Stock Market Stories and Insights

Vertiv Holdings Co. carries a debt of $3.32 billion, with a debt-to-equity (D/E) ratio of 2.68. This suggests that the company significantly depends on borrowed funds for its operations.

Advanced assessment of Vertiv

Vertiv Holdings Co (VRT), a key player in the Electrical Equipment & Parts industry, has been outperforming the market despite a modest decline. With a total revenue of 5.7 billion and a cost of revenue at 4.1 billion, the company has managed to maintain a profit margin of 1.96%.
  over six months ago at Macroaxis 
By Ellen Johnson
Ellen Johnson
Vertiv Holdings Co (VRT), a prominent player in the Electrical Equipment & Parts industry, has been garnering significant attention from analysts in August. With a strong buy consensus from 7 analysts and only 1 hold, confidence in the company's prospects is soaring. Vertiv's robust financial performance, underscored by a net income applicable to common shares of $76.6M and a substantial revenue of $6.1B, has been a key driver of this bullish sentiment.
  over six months ago at Macroaxis 
By Vlad Skutelnik
Vlad Skutelnik
Rhythm Pharmaceuticals (NASDAQ: RYTM), a key player in the Biotechnology industry, continues to exhibit bullish momentum in the US stock market. Despite reporting a net income loss of $181.1M and a diluted EPS of -3.38, the company's market capitalization stands at a robust $1.3B, with an enterprise value of $721.5M. The company, which operates in the Healthcare sector, specifically in Pharmaceuticals, Biotechnology & Life Sciences, has seen a quarterly revenue growth of 6.66%, bringing in revenues of $33.6M.
  over six months ago at Macroaxis 
By Vlad Skutelnik
Vlad Skutelnik
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company in the healthcare sector, has been showing promising signs of potential upside. As of August 2023, the company's valuation market value stands at $24.32, with a Wall Street target price of $36.89 and an analyst target price estimated value of $37.11. This suggests a significant potential upside from the current naive expected forecast value of $26.15.
  over six months ago at Macroaxis 
By Nico Santiago
Nico Santiago
Rhythm Pharmaceuticals, a prominent player in the healthcare and biotechnology sector, has been making waves in the NASDAQ exchange, outperforming expectations and bucking the trend amidst a market downturn. The company's current valuation stands at a robust $721.49M, underpinned by a strong balance sheet with cash reserves of $127.7M and total assets of $382.5M. Despite the company's negative net interest income of $1.2M and a significant free cash flow loss of $177.7M, Rhythm Pharmaceuticals has managed to maintain a low debt to equity ratio of 0.011%, showcasing its financial resilience.
  over six months ago at Macroaxis 
By Raphi Shpitalnik
Raphi Shpitalnik
Rhythm Pharmaceuticals (NASDAQ: RYTM), a prominent player in the Biotechnology industry, is in the spotlight as we move into September. Despite posting a net income loss of $181.1M and a free cash flow deficit of $177.7M, the company's robust financial health is evident in its total stockholder equity of $264.3M, outweighing its total liabilities of $118.2M. The company's change in cash stands at an impressive $68.4M, while the naive expected forecast value is set at 26.15.
  over six months ago at Macroaxis 
By Rifka Kats
Rifka Kats
In the arena of Biotechnology, Rhythm Pharmaceuticals (USA Stocks: RYTM) stands as a notable player. As of August 2023, the company has a substantial market capitalization of 1.3B and an open price of $22.75. Despite a loss in the fiscal year ending December, with an EBITDA of -177.2M, the firm holds promising prospects with a potential upside of 5.34.
  over six months ago at Macroaxis 
By Vlad Skutelnik
Vlad Skutelnik
Powell Industries, a leader in the Electrical Equipment & Parts industry, has been demonstrating a strong financial performance, even amidst a modest market downturn. With a total revenue of 532.6M, an income before tax of 9.8M, and a solid net tangible assets of 296.2M, the company's robust financial health is evident. From a leverage perspective, Powell's prudent management of capital is noteworthy, with capital expenditures at a minimal 2.5M and deferred long-term liabilities at a manageable 7.7M.
  over six months ago at Macroaxis 
By Raphi Shpitalnik
Raphi Shpitalnik
Powell Industries, a prominent player in the Electrical Equipment sector, has been exhibiting dynamic market performance on the NASDAQ exchange, creating unique investment opportunities. Despite the overall analyst consensus being a 'Hold' with one hold recommendation, the company's stock volatility presents potential for both downside and upside price movements. The possible downside price is projected at $68.54, while the potential upside could reach as high as $79.55.
  over six months ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik
Powell Industries currently has $2.32 million in liabilities, with a Debt to Equity (D/E) ratio of 0.01. This may suggest that Powell Industries is not fully leveraging its borrowing potential. The asset utilization indicator refers to the revenue generated for every dollar of assets reported by a company.
  over six months ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik